SCHEMBL19627399

SCHEMBL19627399

CC(C)(C)C(=O)NS(=O)(=O)c1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
FLT1 P17948 1/20 0.54
FLT4 P35916 1/20 0.54
KDR P35968 1/20 0.54
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
HSD11B1 P28845 1/20 0.44
ABCC9 O60706 1/20 0.44
ABCC8 Q09428 1/20 0.44
KCNJ11 Q14654 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19630968 0.82 POLB (0.56) POLBFLT1FLT4KDRSLC1A3
SCHEMBL30754385 0.82 POLB (0.56) POLBFLT1FLT4KDRSLC1A3
SCHEMBL3954909 0.80 POLB (0.58) POLBFLT1FLT4KDRSLC1A3
SCHEMBL10784100 0.80 POLB (0.58) POLBFLT1FLT4KDRSLC1A3
SCHEMBL3335057 0.79 POLB (0.54) POLBFLT1FLT4KDRSLC1A3
SCHEMBL8927095 0.79 POLB (0.54) POLBFLT1FLT4KDRSLC1A3
SCHEMBL6495809 0.79 CA12 (0.50) POLBFLT1FLT4KDRSLC1A3
SCHEMBL2351670 0.79 POLB (0.56) POLBFLT1FLT4KDRSLC1A3
SCHEMBL29543742 0.79 POLB (0.56) POLBFLT1FLT4KDRSLC1A3
SCHEMBL19630982 0.78 POLB (0.52) POLBFLT1FLT4KDRSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, NR1H4 POLB 3973/4885FLT1 3961/4885FLT4 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.